Skip Nav Destination
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
Issue Archive
March 17 2016
In this Issue
Table of Contents
BLOOD FLASHBACK
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents
CME
Marcin W. Wlodarski,Shinsuke Hirabayashi,Victor Pastor,Jan Starý,Henrik Hasle,Riccardo Masetti,Michael Dworzak,Markus Schmugge,Marry van den Heuvel-Eibrink,Marek Ussowicz,Barbara De Moerloose,Albert Catala,Owen P. Smith,Petr Sedlacek,Arjan C. Lankester,Marco Zecca,Victoria Bordon,Susanne Matthes-Martin,Jonas Abrahamsson,Jörn Sven Kühl,Karl-Walter Sykora,Michael H. Albert,Bartlomiej Przychodzien,Jaroslaw P. Maciejewski,Stephan Schwarz,Gudrun Göhring,Brigitte Schlegelberger,Annámaria Cseh,Peter Noellke,Ayami Yoshimi,Franco Locatelli,Irith Baumann,Brigitte Strahm,Charlotte M. Niemeyer,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS,for the EWOG-MDS
BLOOD FORUM
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States
Clinical Trials & Observations
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
Clinical Trials & Observations
Andreas Viardot,Marie-Elisabeth Goebeler,Georg Hess,Svenja Neumann,Michael Pfreundschuh,Nicole Adrian,Florian Zettl,Martin Libicher,Cyrus Sayehli,Julia Stieglmaier,Alicia Zhang,Dirk Nagorsen,Ralf C. Bargou
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use
Clinical Trials & Observations
Ida Martinelli,Anthonie W. A. Lensing,Saskia Middeldorp,Marcel Levi,Jan Beyer-Westendorf,Bonno van Bellen,Henri Bounameaux,Timothy A. Brighton,Alexander T. Cohen,Mila Trajanovic,Martin Gebel,Phuong Lam,Philip S. Wells,Martin H. Prins
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation
Kellie R. Machlus,Stephen K. Wu,Deborah J. Stumpo,Thomas S. Soussou,David S. Paul,Robert A. Campbell,Hermann Kalwa,Thomas Michel,Wolfgang Bergmeier,Andrew S. Weyrich,Perry J. Blackshear,John H. Hartwig,Joseph E. Italiano, Jr
RED CELLS, IRON, AND ERYTHROPOIESIS
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors
Brian M. Dulmovits,Abena O. Appiah-Kubi,Julien Papoin,John Hale,Mingzhu He,Yousef Al-Abed,Sebastien Didier,Michael Gould,Sehba Husain-Krautter,Sharon A. Singh,Kyle W. H. Chan,Adrianna Vlachos,Steven L. Allen,Naomi Taylor,Philippe Marambaud,Xiuli An,Patrick G. Gallagher,Narla Mohandas,Jeffrey M. Lipton,Johnson M. Liu,Lionel Blanc
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
Clinical Trials & Observations
Marco Mielcarek,Terry Furlong,Paul V. O’Donnell,Barry E. Storer,Jeannine S. McCune,Rainer Storb,Paul A. Carpenter,Mary E. D. Flowers,Frederick R. Appelbaum,Paul J. Martin
LETTERS TO BLOOD
Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2
Erik B. van den Akker,Steven J. Pitts,Joris Deelen,Matthijs H. Moed,Shobha Potluri,Jeroen van Rooij,H. Eka D. Suchiman,Nico Lakenberg,Wesley J. de Dijcker,André G. Uitterlinden,Robert Kraaij,Albert Hofman,Anton J. M. de Craen,Jeanine J. Houwing-Duistermaat,Gert-Jan B. van Ommen,on behalf of the Genome of The Netherlands Consortium,David R. Cox,Joyce B. J. van Meurs,Marian Beekman,Marcel J. T. Reinders,P. Eline Slagboom
BLOOD WORK
ERRATA
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Carotid artery section (hematoxylin and eosin staining) from a mouse with high lysyl oxidase expression in platelets. Large thrombus resulting from ferric chloride-induced endothelial injury is shown. See the article by Matsuura et al on page 1493.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals